With these premises, we advise future studies to have these features: a prospective, preferably randomized, design, with adequate sample size calculation, including patients in OCPs, standardized glucose monitoring and IS estimation metrics, observed changes in glycaemic control in fasting and postprandial conditions, including data on insulin administration (AHCL, CSII and MDI), and the collection of data on lifestyle and diabetes care habits. The gene discussed is INS; the disease is diabetes mellitus.